Corporate Information – Page 23 – Alligator Bioscience

2019-01-07

Alligator Bioscience launches RUBY™, a novel concept in bispecific antibody formats

Priority filling submitted RUBY™ bispecific concept has been developed to achieve an outstanding stability, manufacturability and shorter de ...

2018-12-11

Regulatory

A first-in-class bispecific CTLA-4 antibody Lund, Sweden, December 11, 2018 – Alligator Bioscience AB (Nasdaq Stockholm: ATORX) today announ ...

2018-12-10

The science behind the Nobel Prizes in Medicine and Chemistry is the core in Alligator's research and development Read the full magazine ...

2018-11-09

Regulatory

Data Show That ALG.APV-527 Selectively Activates and Enhances Tumor-directed T-cell and Natural Killer (NK) Cell Responses Targets 5T4 Cance ...

2018-11-07

Regulatory

Lund, Sweden, November 7, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that it will receive payments of more than U ...

2018-11-06

Lund, Sweden, November 6, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceu ...

2018-10-30

Regulatory

New candidate drug selected – the bispecific tumor-localizing CTLA-4 x GITR antibody ATOR-1144 Lund, Sweden, October 30, 2018 – Alligator Bi ...

2018-10-05

Lund, Sweden, October 5, 2018 – Alligator Bioscience AB (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmac ...

2018-09-28

Regulatory

Lund, Sweden, September 28, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmac ...